Viant Technology Inc (DSP) Q4 2025 Earnings Call Transcript

Why It Matters

The results underscore Vanda’s ability to grow its core psychiatry franchise while diversifying into new therapeutic areas, positioning the firm for sustained revenue expansion despite generic erosion and higher cash burn.

Key Takeaways

• Fanapt sales rose 24% to $117.3M.
• Tradipitant approved for motion sickness, launch Q2/Q3 2026.
• HETLIOZ sales fell amid generic competition.
• Cash down to $263.8M, higher burn expected.
• 2026 revenue guidance $230‑260M, excluding new launches.

Pulse Analysis

Vanda’s 2025 earnings highlight a rare combination of commercial momentum and strategic pipeline advancement. Fanapt, the company’s flagship antipsychotic, delivered a 24% jump in net product sales, buoyed by a 28% rise in total prescriptions and a 149% surge in new‑to‑brand starts. The expansion of the Fanapt sales force from roughly 160 to 300 representatives amplified face‑to‑face prescriber engagement, translating into an 8% year‑over‑year revenue lift in the fourth quarter. This growth helped offset the modest decline in HETLIOZ, which continues to lose market share to generics, and contributed to a total revenue increase of $19.5 million despite a $120.5 million net loss driven by a large non‑cash tax valuation allowance.

Regulatory milestones further broaden Vanda’s addressable market. The FDA’s approval of tradipitant (branded Nirius) introduces the first oral agent for motion‑sickness vomiting in four decades, targeting a sizable patient base of up to 78 million U.S. adults who experience travel‑related nausea. The company is also positioning Nirius for label expansion into GLP‑1‑agonist‑induced vomiting, a side effect affecting half of patients on popular diabetes and obesity drugs. Concurrently, the Vasanti (melperone) NDA is under review with a PDUFA date of February 21 2026, and the imsidolimab BLA for generalized pustular psoriasis moves toward potential approval, adding long‑term revenue streams and extending patent exclusivity into the late 2030s.

Financially, Vanda entered year‑end with $263.8 million in cash, a decline of $110.8 million reflecting higher SG&A spend, R&D outlays, and the deferred tax charge. Management warned that 2026 cash burn could exceed 2025 levels as milestone payments and commercial infrastructure investments ramp up. Nonetheless, the company’s guidance of $230‑260 million in product revenue, excluding any upside from Nirius or Vasanti launches, signals confidence in its core portfolio’s growth trajectory. Investors will watch how the expanded sales force, upcoming product launches, and late‑stage pipeline candidates translate into top‑line momentum while balancing the heightened expense profile.